News By: Jeremy Glunt

As it enthusiastically embraces aspects of decentralized clinical trials (DCTs), the drug and device development industry is running the risk of “leapfrogging over [study] sites and forgetting about them as a key stakeholder” in the enterprise, says Mary Costello, Head of the Site and Investigator Network, Medable.

New research finds that FDA could enhance public safety by employing new data-driven approaches to identify adverse effects of drugs faster and more reliably, which would improve the regulatory decision-making and oversight processes.

The European Commission (EC) has released extensive recommendations for sponsors covering best practices for the development, translation, and distribution of lay summaries of clinical trial information, intended both for trial […]

A new report on how trends in market growth for virtual clinical trials are expected to play out in the next five years indicates an anticipation for a compound annual […]

These are exciting times to be a member of the Association of Clinical Research Professionals (ACRP). Just as the challenge of Covid-19 inspired clinical trial practitioners to attain new heights […]